Tarsus Pharmaceuticals (TARS) News Today $51.33 -1.03 (-1.97%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$51.32 -0.01 (-0.02%) As of 03/25/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opthea Limited Sponsored ADR (OPT) and Larimar Therapeutics (LRMR)March 25 at 3:51 PM | markets.businessinsider.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 2.9% - Time to Sell?Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Down 2.9% - What's Next?March 25 at 1:09 PM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Sells $107,085.07 in StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne C. Whitfield sold 2,137 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the transaction, the insider now owns 46,355 shares in the company, valued at $2,322,849.05. This represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Dianne C. Whitfield Sells 2,315 SharesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the sale, the insider now owns 50,751 shares of the company's stock, valued at approximately $2,349,263.79. This represents a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 21, 2025 | marketbeat.comBryan Wahl Sells 3,084 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) General Counsel Bryan Wahl sold 3,084 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $154,539.24. Following the completion of the transaction, the general counsel now owns 51,712 shares in the company, valued at $2,591,288.32. The trade was a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.March 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells $154,654.89 in StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.March 21, 2025 | marketbeat.comBobak R. Azamian Sells 7,131 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak R. Azamian sold 7,131 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the transaction, the chief executive officer now directly owns 70,720 shares in the company, valued at $3,273,628.80. The trade was a 9.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak R. Azamian Sells 8,534 SharesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak R. Azamian sold 8,534 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $427,638.74. Following the transaction, the chief executive officer now owns 53,635 shares in the company, valued at $2,687,649.85. This trade represents a 13.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 21, 2025 | marketbeat.comDianne C. Whitfield Sells 2,137 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) StockMarch 21, 2025 | insidertrades.comTarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50March 13, 2025 | markets.businessinsider.comTarsus prices $125M stock offeringMarch 13, 2025 | msn.comTarsus Pharmaceuticals announces $100M common stock offeringMarch 12, 2025 | markets.businessinsider.comTarsus Announces Pricing of Upsized $125.0 Million Public OfferingMarch 12, 2025 | globenewswire.comTarsus Announces Proposed $100.0 Million Public OfferingMarch 12, 2025 | globenewswire.comTarsus Pharma: Strong Execution In Xdemvy CommercializationMarch 11, 2025 | seekingalpha.comPacira Pharmaceuticals (PCRX) Receives a Hold from BarclaysMarch 10, 2025 | markets.businessinsider.comEssex Investment Management Co. LLC Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Essex Investment Management Co. LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,760March 10, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by BrokeragesShares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have given a bMarch 9, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc.March 8, 2025 | cnn.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 5.8% After Analyst UpgradeTarsus Pharmaceuticals (NASDAQ:TARS) Shares Up 5.8% Following Analyst UpgradeMarch 8, 2025 | marketbeat.comLisanti Capital Growth LLC Has $5.37 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Lisanti Capital Growth LLC increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 143.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,935 shares of the company's stoMarch 8, 2025 | marketbeat.comAigen Investment Management LP Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Aigen Investment Management LP purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 7,504 shares of the company's stock, valued atMarch 8, 2025 | marketbeat.comJefferies Financial Group Issues Positive Forecast for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock PriceJefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday.March 7, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferenceMarch 6, 2025 | globenewswire.comTarsus Pharmaceuticals price target raised to $58 from $54 at JefferiesMarch 6, 2025 | markets.businessinsider.comSeattle biotech launches with $187 million for cancer treatmentsMarch 4, 2025 | bizjournals.comOppenheimer Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)March 3, 2025 | markets.businessinsider.comARS Pharmaceuticals (SPRY) Receives a Buy from William BlairMarch 3, 2025 | markets.businessinsider.comWhat is HC Wainwright's Forecast for TARS Q1 Earnings?Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Wednesday, February 26th. HC Wainwright analyst O. Livnat expects that the company will earn ($0.80) perMarch 1, 2025 | marketbeat.comLifesci Capital Weighs in on TARS Q1 EarningsTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Stock analysts at Lifesci Capital issued their Q1 2025 earnings per share estimates for shares of Tarsus Pharmaceuticals in a report issued on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville anticipates that the company wiMarch 1, 2025 | marketbeat.comWilliam Blair Issues Pessimistic Outlook for TARS EarningsTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at William Blair dropped their Q1 2025 EPS estimates for Tarsus Pharmaceuticals in a report issued on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($March 1, 2025 | marketbeat.comQ1 Earnings Forecast for TARS Issued By William BlairTarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 25th. William Blair analyst L. HaFebruary 28, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TARS Q4 Earnings?Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities researchers at HC Wainwright issued their Q4 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Wednesday, February 26th. HC Wainwright analyst O. Livnat forecasts that the company wFebruary 28, 2025 | marketbeat.comY Intercept Hong Kong Ltd Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)Y Intercept Hong Kong Ltd acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,118 shares of the company's stock, valued at apprFebruary 28, 2025 | marketbeat.comTarsus Pharmaceuticals’ Earnings Call Highlights Success and ChallengesFebruary 27, 2025 | tipranks.comWhat is Lifesci Capital's Estimate for TARS FY2025 Earnings?Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Investment analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville anticipates that the company will pFebruary 27, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | msn.comTarsus Pharmaceuticals price target lowered to $60 from $62 at BarclaysFebruary 26, 2025 | markets.businessinsider.comGuggenheim ups Tarsus Pharmaceuticals price target, would buy on weaknessFebruary 26, 2025 | markets.businessinsider.comBarclays Lowers Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $60.00Barclays cut their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday.February 26, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)HC Wainwright reaffirmed a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday.February 26, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call TranscriptFebruary 25, 2025 | seekingalpha.comTarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call TranscriptFebruary 25, 2025 | seekingalpha.comTarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business AchievementsFebruary 25, 2025 | finance.yahoo.comTarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business AchievementsFebruary 25, 2025 | finance.yahoo.comTarsus Pharmaceuticals price target lowered to $70 from $75 at BofAFebruary 25, 2025 | markets.businessinsider.comTarsus Pharmaceuticals price target lowered to $70 from $75 at BofAFebruary 25, 2025 | markets.businessinsider.comTarsus Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 25, 2025 | seekingalpha.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up on Better-Than-Expected EarningsTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up on Strong EarningsFebruary 25, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings ResultsTarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.February 25, 2025 | marketbeat.com Remove Ads Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Media Mentions By Week TARS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TARS News Sentiment▼0.150.77▲Average Medical News Sentiment TARS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TARS Articles This Week▼164▲TARS Articles Average Week Remove Ads Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Sarepta Therapeutics News Revolution Medicines News BridgeBio Pharma News Lantheus News TG Therapeutics News Legend Biotech News Axsome Therapeutics News Telix Pharmaceuticals Limited American Depositary Shares News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TARS) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARS Stock Free TARS Stock Alerts